Cargando…

Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings

BACKGROUND: A see on cardiovascular diseases and bladder cancer. The changes to the patterns of rosiglitazone and pioglitazone utilisation in Australia following the timing of these various health authority warnings such as the Australian Therapeutic Good Administration (TGA), European Medicines Age...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niyomnaitham, Suvimol, Page, Andrew, La Caze, Adam, Whitfield, Karen, Smith, Alesha J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994196/ https://www.ncbi.nlm.nih.gov/pubmed/24708579 http://dx.doi.org/10.1186/1472-6963-14-151

Ejemplares similares

Influence of health warnings on the use of rosiglitazone and pioglitazone in an area of Spain: A time-series study
por: Carracedo-Martínez, Eduardo, et al.
Publicado: (2016)

Rosiglitazone and Pioglitazone Utilization from January 2007 Through May 2008 Associated With Five Risk-Warning Events
por: Starner, Catherine I., et al.
Publicado: (2008)

Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database
por: Berthet, Stephanie, et al.
Publicado: (2011)

Rosiglitazone and Pioglitazone Alter Aromatase Kinetic Properties in Human Granulosa Cells
por: Araki, Takako, et al.
Publicado: (2011)

The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety
por: Leonard, Charles E., et al.
Publicado: (2020)

Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study
por: Juurlink, David N, et al.
Publicado: (2009)

Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies
por: Deeg, Mark A., et al.
Publicado: (2008)

Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs
por: Colhoun, H. M., et al.
Publicado: (2012)

Development of Heart Failure in Medicaid Patients with Type 2 Diabetes Treated with Pioglitazone, Rosiglitazone, or Metformin
por: Breunig, Ian M., et al.
Publicado: (2014)

Dual therapy of rosiglitazone/pioglitazone with glimepiride on diabetic nephropathy in experimentally induced type 2 diabetes rats
por: Rao, Ravi Prakash, et al.
Publicado: (2011)

Trends in dispensing and utilisation of sustained-release tapentadol in Australia.
por: Camacho, Ximena, et al.
Publicado: (2022)

Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs
por: Ahuja, Vishal, et al.
Publicado: (2015)

Trends in the utilisation of aged care services in Australia, 2008–2016
por: Khadka, Jyoti, et al.
Publicado: (2019)

Utilization and Costs for Compliant Patients Initiating Therapy With Pioglitazone or Rosiglitazone Versus Insulin in a Medicaid Fee-for-Service Population
por: Kalsekar, Iftekhar, et al.
Publicado: (2006)

Bioequivalence Study of 100-mg Cilostazol Tablets in Healthy Thai Adult Volunteers
por: Chatsiricharoenkul, Somruedee, et al.
Publicado: (2019)

Evaluation of the Safety and Immunogenicity of Fractional Intradermal COVID-19 Vaccines as a Booster: A Pilot Study
por: Niyomnaitham, Suvimol, et al.
Publicado: (2022)

Safety and efficacy of rosiglitazone in the elderly diabetic patient
por: Viljoen, Adie, et al.
Publicado: (2009)

Unmasking Differential Effects of Rosiglitazone and Pioglitazone in the Combination Treatment with n-3 Fatty Acids in Mice Fed a High-Fat Diet
por: Kus, Vladimir, et al.
Publicado: (2011)

Comparative efficacy and acceptability of licensed dose intranasal corticosteroids for moderate-to-severe allergic rhinitis: a systematic review and network meta-analysis
por: Soe, Kay Khine, et al.
Publicado: (2023)

Expenditure and resource utilisation for cervical screening in Australia
por: Lew, Jie-Bin, et al.
Publicado: (2012)

Leukemia and rosiglitazone
por: Yavasoglu, Irfan, et al.
Publicado: (2016)

Improving pharmacy practice in relation to complementary medicines: a qualitative study evaluating the acceptability and feasibility of a new ethical framework in Australia
por: Popattia, Amber Salman, et al.
Publicado: (2021)

Safety and tolerability of adjunctive rosiglitazone treatment for children with uncomplicated malaria
por: Varo, Rosauro, et al.
Publicado: (2017)

Rosiglitazone Prior Authorization Safety Policy: A Cohort Study
por: Starner, Catherine I., et al.
Publicado: (2012)

Contemporary trends in anaphylaxis burden and healthcare utilisation in Western Australia: A linked data study
por: Stiles, Samantha L., et al.
Publicado: (2023)

The Janus face of rosiglitazone
por: Pich, Christine, et al.
Publicado: (2018)

Use of rosiglitazone before and after vascular injury in hypercholesterolemic rabbits: Assessment of neointimal formation
por: Alessi, Alexandre, et al.
Publicado: (2008)

Pioglitazone use in Australia and the United Kingdom following drug safety advisories on bladder cancer risk: An interrupted time series study
por: Kemp‐Casey, Anna, et al.
Publicado: (2022)

Physiotherapy utilisation and costs before lumbar spine surgery: a retrospective analysis of workers compensation claims in Australia
por: Zadro, Joshua R., et al.
Publicado: (2021)

Safety and immunogenicity of intradermal administration of fractional dose CoronaVac(®), ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination
por: Chatsiricharoenkul, Somruedee, et al.
Publicado: (2022)

Cross-sector, sessional employment of pharmacists in rural hospitals in Australia and New Zealand: a qualitative study exploring pharmacists’ perceptions and experiences
por: Tan, Amy CW, et al.
Publicado: (2014)

Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers
por: Angkasekwinai, Nasikarn, et al.
Publicado: (2022)

Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: A randomized trial
por: Niyomnaitham, Suvimol, et al.
Publicado: (2022)

Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2017)

Exploring the Utilisation of Stand up Paddle Boarding in Australia
por: Schram, Ben, et al.
Publicado: (2017)

Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review
por: Desouza, Cyrus V., et al.
Publicado: (2010)

Anticipating the unimaginable: Heat Health Warning Systems in Europe and Australia
por: Parkes, M, et al.
Publicado: (2022)

Rosiglitazone and Fenofibrate Additive Effects on Lipids
por: Slim, Ahmad, et al.
Publicado: (2011)

Safety and Effectiveness of Rosiglitazone in Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease
por: Wang, Chao-Hung, et al.
Publicado: (2006)

Determining the obligations of the pharmaceutical industry during the pandemic
por: La Caze, Adam
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tu143ub3qan73ivvl4qnhv2mna